Immune checkpoint inhibitors for the treatment of melanoma.

ABSTRACT:

Introduction

Immune checkpoint inhibitor (ICI) based immunotherapy is dramatically changing the management of many types of cancers including melanoma. In this malignancy, ICIs prolong disease and progression-free survival as well as overall survival of a percentage of treated patients, becoming the cornerstone of melanoma treatment.

Areas covered

In this review, first, we will describe the mechanisms of immune checkpoint activation and inhibition, second, we will summarize the results obtained with ICIs in melanoma treatment in terms of efficacy as well as toxicity, third, we will discuss the potential mechanisms of immune escape from ICI, and lastly, we will review the potential predictive biomarkers of clinical efficacy of ICI-based immunotherapy in melanoma.

Expert op

SUBMITTER: Sabbatino F 

PROVIDER: S-EPMC9038682 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature